Skip to content
Medical Health Aged Care

Victorian Opposition’s free MenB vaccine commitment ‘will save young lives’: GPs

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has welcomed a commitment from the Victorian Liberals and Nationals to provide free vaccinations against deadly meningococcal B infections.

Meningococcal B infections can cause meningitis (brain inflammation) or septicaemia (blood poisoning) resulting in rapid death or disability including brain damage and limb loss. Victoria has recorded 14 cases of meningococcal B this year.

RACGP Victoria again called for the State Government to match other jurisdictions by providing free vaccines to at-risk groups following the passing of 16-year-old Levi Syer, who died shortly after developing symptoms of the deadly bacterial infection.

While the meningococcal ACWY vaccine is free under the National Immunisation Program for all children and young people, the vaccine against the B strain is not provided for all children and for most requires an out-of-pocket payment of $110–150 per dose. Both are recommended in the Australian Immunisation Handbook.

RACGP Vicotria Chair Dr Anita Muñoz praised the commitment from the Opposition.

“We’ve seen how much of a difference this protection makes just two months ago with the death of Levi Syer,” she said.

“Meningitis isn’t predictable, but it is preventable through vaccination. It shouldn’t be on families to ensure they’re protected against all strains – that’s why we’ve got a health system.

“Levi died about a day after he first fell ill. That’s shockingly common for meningococcal B infections. Making the MenB vaccine accessible for all Victorians will save young lives.

“Our children and young people deserve better. Other jurisdictions have provided this protection free of charge, but Victorians have to seek it out and pay out of pocket.”

Free meningococcal B vaccines for those aged two and under and every teen aged 15–19 has been part of the RACGP’s longstanding advocacy.

“This disease kills about one in 10 patients and leaves up to 20% of those who survive with permanent brain damage, hearing loss or a learning disability,” Dr Muñoz said.

“Since the MenC and then MenACWY vaccines were introduced, meningococcal B has become the leading cause of meningococcal disease, accounting for 83% of cases. Yet we’ve got a safe and effective MenB vaccine.

“We can and should get to zero deaths. We know how to do it, and we’ve sadly seen why we should.”

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Senior Media Advisor

Stuart Winthrope
Media Advisor

Kevin Diggerson
Public Affairs Manager

Contact: 03 8699 0992[email protected]

Follow us on X and Facebook.

Media

More from this category

  • Medical Health Aged Care
  • 26/02/2026
  • 23:11
Kairos Pharma, Ltd

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. LOS ANGELES--BUSINESS WIRE--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer…

  • Medical Health Aged Care
  • 26/02/2026
  • 22:12
BeOne Medicines Ltd.

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 26/02/2026
  • 16:34
Australian Primary Health Care Nurses Association (APNA)

MEDIA RELEASE: APNA welcomes Senate Committee recommendation?

The Australian Primary Health Care Nurses Association (APNA) warmly welcomes the recommendation of the Senate Community Affairs Committee that theSenatepass the Health Legislation Amendment (Prescribing of Pharmaceutical Benefits) Bill 2025.  TheSenate Committee reportis a significant step in the journey towards allowing authorised registered nurse prescribers to prescribe under the Pharmaceutical Benefits Scheme (PBS).  APNA President Denise Lyons said the recommendation is a win for patients, communities, and the health system, and reflects a clear recognition of the vital role nurses play in delivering timely, safe and accessible healthcare.  “This is an important stepfor Australia’s primary health care system,” Denise said.  "Allowing highly experienced, skilled and trusted nurses…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.